AVP and breast cancer: The lack of detailed follow-up and risk-reduction guidance for women with ADH, ALH and LCIS is at odds with other high-risk groups, such as those with a strong family history of BC, for whom the National Institute for Health and Care Excellence (NICE) recommends tailored screening and prevention approaches [14].